However, the authors acknowledged in their discussion that, “We could not demonstrate a vimentin-specific response in all sarcoidosis patients. In this respect, it is also important to note that there was no clinical difference (e.g., radiological stage of disease at presentation, age of patient, need for subsequent immunosuppression therapy) between vimentin responders and non-responders.”
You Might Also Like
Also By This Author
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
- Eberhardt C, Thillai M, Parker R, et al. Proteomic analysis of Kveim Reagent identifies targets of cellular immunity in sarcoidosis. PLoS One. 2017 Jan 23;12(1):e0170285. doi: 10.1371/journal.pone.0170285. eCollection 2017.